301166 优宁维
已收盘 04-30 15:00:00
资讯
新帖
简况
优宁维:公司对外投资收购,主要围绕现有主营业务,寻找具有协同效应的标的企业,以实现经营业绩不断提升
证券之星 · 04-26
优宁维:公司对外投资收购,主要围绕现有主营业务,寻找具有协同效应的标的企业,以实现经营业绩不断提升
优宁维(301166.SZ)发布一季度业绩,净利润520.25万元,下降70.97%
智通财经 · 04-26
优宁维(301166.SZ)发布一季度业绩,净利润520.25万元,下降70.97%
优宁维(301166)2023年年报简析:增收不增利,三费占比上升明显
证券之星 · 04-24
优宁维(301166)2023年年报简析:增收不增利,三费占比上升明显
优宁维最新公告:2023年净利润同比下降62%至4032万元
证券之星 · 04-22
优宁维最新公告:2023年净利润同比下降62%至4032万元
优宁维(301166.SZ)发布2023年度业绩,净利润4031.88万元,下降62.18%
智通财经 · 04-22
优宁维(301166.SZ)发布2023年度业绩,净利润4031.88万元,下降62.18%
【异动股】千金藤素板块下挫,优宁维(301166.CN)跌1.9%
财华社 · 02-23
【异动股】千金藤素板块下挫,优宁维(301166.CN)跌1.9%
优宁维2023净利预降 上市即巅峰超募13亿民生证券保荐
中国经济网 · 01-29
优宁维2023净利预降 上市即巅峰超募13亿民生证券保荐
优宁维(301166.SZ)发预减,预计2023年度净利润4000万元至5500万元,同比下降48.35%至62.44%
智通财经网 · 01-26
优宁维(301166.SZ)发预减,预计2023年度净利润4000万元至5500万元,同比下降48.35%至62.44%
加载更多
公司概况
公司名称:
上海优宁维生物科技股份有限公司
所属行业:
批发业
上市日期:
2021-12-28
主营业务:
上海优宁维生物科技股份有限公司是一家面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务的科学服务商。公司主要产品及服务有生命科学试剂、生命科学仪器及耗材、综合技术服务。目前公司提供生命科学产品SKU约870万种,覆盖基因、蛋白、细胞、组织及动物等不同水平的研究对象,涵盖生命科学基础研究、医学基础研究、体外诊断研究、药物研发、细胞治疗研究等领域,是国内生命科学产品种类及规格最全面的供应商之一。
发行价格:
86.06
{"stockData":{"symbol":"301166","market":"SZ","secType":"STK","nameCN":"优宁维","latestPrice":30.61,"timestamp":1714460601000,"preClose":29.7,"halted":0,"volume":1335505,"delay":0,"floatShares":41268900,"shares":86666700,"eps":0.3185,"marketStatus":"已收盘","marketStatusCode":5,"change":0.91,"latestTime":"04-30 15:00:00","open":30.01,"high":30.99,"low":29.74,"amount":40464700,"amplitude":0.0421,"askPrice":30.62,"askSize":7,"bidPrice":30.61,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.3185,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":29.7,"symbolType":"stock","openAndCloseTimeList":[[1714440600000,1714447800000],[1714453200000,1714460400000]],"highLimit":32.67,"lowLimit":26.73,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":86666668,"pbRate":1.21,"roa":"--","roe":"0.02%","epsLYR":0.47,"committee":0.066667,"marketValue":2653000000,"floatMarketCap":1263000000,"peRate":96.106747,"changeRate":0.0306,"turnoverRate":0.0324,"status":0},"requestUrl":"/m/hq/s/301166","defaultTab":"news","newsList":[{"id":"2430229853","title":"优宁维:公司对外投资收购,主要围绕现有主营业务,寻找具有协同效应的标的企业,以实现经营业绩不断提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2430229853","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430229853?lang=zh_cn&edition=full","pubTime":"2024-04-26 18:04","pubTimestamp":1714125861,"startTime":"0","endTime":"0","summary":"投资者:尊敬的董秘你好,从国际巨头的大型公司来说,要想成长做大做强必须进行产业并购,贵公司上市2年多了,融资了大量现金,迟迟不进行并购,是找不到合适的并购公司吗优宁维董秘:投资者您好,公司对外投资收购,主要围绕现有主营业务,寻找具有协同效应的标的企业,以实现经营业绩不断提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600044215.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430249654","title":"优宁维(301166.SZ)发布一季度业绩,净利润520.25万元,下降70.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430249654","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430249654?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:07","pubTimestamp":1714118860,"startTime":"0","endTime":"0","summary":"智通财经APP讯,优宁维(301166.SZ)发布2024年第一季度报告,该公司营业收入为2.72亿元,同比减少0.91%。归属于上市公司股东的净利润为520.25万元,同比减少70.97%。归属于上市公司股东的扣除非经常性损益的净利润为35.75万元,同比减少96.66%。基本每股收益为0.06元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111432.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429125723","title":"优宁维(301166)2023年年报简析:增收不增利,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2429125723","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429125723?lang=zh_cn&edition=full","pubTime":"2024-04-24 06:23","pubTimestamp":1713911002,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期优宁维发布2023年年报。根据财报显示,本报告期中优宁维增收不增利,三费占比上升明显。截至本报告期末,公司营业总收入12.26亿元,同比上升2.57%,归母净利润4031.88万元,同比下降62.18%。筹资活动产生的现金流量净额变动幅度为-974.88%,原因:本期支付2022年度利润分配及归还银行贷款。证券之星价投圈财报分析工具显示:资产质量方面,公司现金资产非常健康。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400012297.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429910464","title":"优宁维最新公告:2023年净利润同比下降62%至4032万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429910464","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429910464?lang=zh_cn&edition=full","pubTime":"2024-04-22 17:10","pubTimestamp":1713777023,"startTime":"0","endTime":"0","summary":"优宁维发布2023年年度报告,实现营业收入12.26亿元,同比增长2.57%;归属于上市公司股东的净利润4031.88万元,同比下降62.18%。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200019832.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429917167","title":"优宁维(301166.SZ)发布2023年度业绩,净利润4031.88万元,下降62.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429917167","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429917167?lang=zh_cn&edition=full","pubTime":"2024-04-22 17:03","pubTimestamp":1713776604,"startTime":"0","endTime":"0","summary":"智通财经APP讯,优宁维(301166.SZ)发布2023年年度报告,该公司营业收入为12.26亿元,同比增长2.57%。归属于上市公司股东的净利润为4031.88万元,同比减少62.18%。归属于上市公司股东的扣除非经常性损益的净利润为1229.41万元,同比减少85.59%。基本每股收益为0.47元。此外,拟向全体股东每10股派发现金红利4.7元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106538.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2413018782","title":"【异动股】千金藤素板块下挫,优宁维(301166.CN)跌1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413018782","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2413018782?lang=zh_cn&edition=full","pubTime":"2024-02-23 10:45","pubTimestamp":1708656326,"startTime":"0","endTime":"0","summary":"今日早盘,截至10:45,千金藤素板块下挫。优宁维(301166.CN)跌1.90%报29.87元,皓元医药(688131.CN)跌1.45%报34.58元,方盛制药(603998.CN)跌1.38%报9.31元,步长制药(603858.CN)跌1.06%报16.85元,云南白药(000538.CN)跌0.44%报49.76元。","market":"other","thumbnail":"https://www.finet.hk/images/news_default.jpg","type":0,"news_type":0,"thumbnails":["https://www.finet.hk/images/news_default.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/65d806c69dfc4250c48f406c","is_publish_highlight":false,"gpt_icon":0},{"id":"2407889293","title":"优宁维2023净利预降 上市即巅峰超募13亿民生证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2407889293","media":"中国经济网","top":-1,"share":"https://www.laohu8.com/m/news/2407889293?lang=zh_cn&edition=full","pubTime":"2024-01-29 13:48","pubTimestamp":1706507280,"startTime":"0","endTime":"0","summary":" 2022年,优宁维归属于上市公司股东的净利润10,648.51万元,扣除非经常性损益后的净利润8,518.69万元。优宁维的保荐机构为民生证券股份有限公司,保荐代表人为梁军、卞进。 上市次日,优宁维盘中创下股价最高点136元,此后股价震荡下跌。优宁维最终募集资金净额比原计划多13.12亿元。 优宁维发行费用合计2.69亿元,民生证券股份有限公司获得承销及保荐费用2.48亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-01-29/doc-inafekhk8415109.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-01-29/doc-inafekhk8415109.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2406228753","title":"优宁维(301166.SZ)发预减,预计2023年度净利润4000万元至5500万元,同比下降48.35%至62.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2406228753","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2406228753?lang=zh_cn&edition=full","pubTime":"2024-01-26 16:56","pubTimestamp":1706259360,"startTime":"0","endTime":"0","summary":"优宁维披露2023年度业绩预告,公司预计归属于上市公司股东的净利润4000万元至5500万元,同比下降48.35%至62.44%;扣除非经常性损益后的净利润1400万元至2100万元,同比下降75.35%至83.57%。股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-26/doc-inaevxma4619749.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-26/doc-inaevxma4619749.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-12-28","address":"上海市杨浦区控江路1690号1505室","stockEarnings":[{"period":"1week","weight":0.0952},{"period":"1month","weight":0.0156},{"period":"3month","weight":0.0737},{"period":"6month","weight":-0.2712},{"period":"1year","weight":-0.3402},{"period":"ytd","weight":-0.2033}],"companyName":"上海优宁维生物科技股份有限公司","boardCode":"AI0051","perCapita":"3527股","boardName":"批发业","registeredCapital":"8666万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":" 上海优宁维生物科技股份有限公司是一家面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务的科学服务商。公司主要产品及服务有生命科学试剂、生命科学仪器及耗材、综合技术服务。目前公司提供生命科学产品SKU约870万种,覆盖基因、蛋白、细胞、组织及动物等不同水平的研究对象,涵盖生命科学基础研究、医学基础研究、体外诊断研究、药物研发、细胞治疗研究等领域,是国内生命科学产品种类及规格最全面的供应商之一。","serverTime":1714692908274,"listedPrice":86.06,"stockholders":"11700人(较上一季度减少8.91%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"优宁维,301166,优宁维股票,优宁维股票老虎,优宁维股票老虎国际,优宁维行情,优宁维股票行情,优宁维股价,优宁维股市,优宁维股票价格,优宁维股票交易,优宁维股票购买,优宁维股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}